GILD

Gilead Sciences
D

GILD

110.350
USD
0.05
(0.05%)
مغلق
حجم التداول
338,808
الربح لكل سهم
8
العائد الربحي
2.83
P/E
24
حجم السوق
137,267,578,502
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 9 أشهر
buy
2024-10-30 09:50
GILD Chart
المزيد
أصول ذات صلة
ABBV
ABBV
2.670
(1.36%)
198.950 USD
AMGN
AMGN
-0.02
(-0.01%)
284.68 USD
BIIB
BIIB
-1.730
(-1.34%)
127.690 USD
INCY
INCY
0.575
(0.74%)
78.230 USD
MRK
MRK
0.940
(1.18%)
80.380 USD
NVS
NVS
2.450
(2.16%)
115.980 USD
PFE
PFE
0.313
(1.31%)
24.250 USD
REGN
REGN
5.11
(0.92%)
560.19 USD
SNY
SNY
1.225
(2.65%)
47.410 USD
المزيد
الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).